An increase in January home prices lifted the markets to a higher open with the Dow gaining 40 points to 20,591. Nasdaq rose 3 points to 5,844.
On the upside
The Korean Ministry of Food and Drug Safety approved Catalyst Biosciences' (Nasdaq: CBIO) Investigational New Drug Application for CB 2679d/ISU304.
Akers Biosciences (Nasdaq: AKER) received an initial order for its rapid cholesterol self-test from First Check Diagnostics.
Power Solutions (Nasdaq: PSIX) entered a strategic investment and collaboration agreement with Weichai America.
On the downside
Cryoport (Nasdaq: CRYX) priced its public offering of 5.5 million common shares at the discounted price of $2.00 per share.
Investors locked in profits on Regulus Therapeutics (Nasdaq: RGLS).
Qatar Investment Authority will sell up to $900 million worth of its holdings in Banco Santander's (NYSE: BSBR) Brazilian unit.
In the broad market, declining issues outpaced advancers by a margin of nearly 10 to 9 on the NYSE and by a margin of 9 to 7 on Nasdaq. The broader S&P 500 index rose 3 points to 2,345. Bitcoin climbed $23 to $1063.
